GET DAILY SIGNALSRoyalty Pharma (RPRX) Posts +9% Rise in Q3 Portfolio Receipts and Raises Guidance
Key Takeaways
- Royalty Pharma reported third quarter 2026 Portfolio Receipts of $890 million, up 9% from $814 million a year earlier.
- Royalty Receipts — the company's recurring cash inflows — rose 9% to $883 million and grew 12% through the first nine months of 2026.
- Reported earnings of $1.21 per share exceeded the $1.18 consensus, while GAAP net income fell to $145 million, weighed down by a $150 million non-cash impairment tied to Novartis' pelacarsen.
- Management raised full-year 2026 Portfolio Receipts guidance for the third consecutive quarter, to $3.50 billion–$3.55 billion, implying Royalty Receipts growth of 10%–11%.
- Royalty Pharma added three new royalties during the quarter — Zoryve, Mimrylo, and cliramitug — bringing 2026 announced transaction value to $1.9 billion.
- Adjusted EBITDA was $840 million, and Portfolio Cash Flow reached $673 million.
Why These Results Matter
Royalty Pharma's third quarter results matter because the company's entire business model depends on the durability and diversification of its royalty portfolio. As a royalty aggregator, Royalty Pharma collects payments tied to sales of therapies developed by partners rather than selling drugs itself. Investors closely watch whether growth from newer franchises such as Tremfya, Voranigo, Evrysdi, and Imdelltra can offset structural declines in legacy royalties like Promacta and Imbruvica. The quarter also carried portfolio-specific risks, including the failed Phase 3 trial for Novartis' pelacarsen. Against that backdrop, the results offered a direct read on management's ability to redeploy cash into value-enhancing royalty acquisitions while sustaining shareholder returns through dividends and buybacks. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Quarter in Detail
For the third quarter ended September 30, 2026, Royalty Pharma reported Portfolio Receipts of $890 million, a 9% increase from $814 million in the prior-year period. Royalty Receipts rose 9% to $883 million, driven by strong performances from Tremfya, Voranigo, Evrysdi, and Imdelltra, which absorbed an approximately 5% combined headwind from declines in Promacta and Imbruvica.
On a GAAP basis, total income and other revenues were $690 million, up 13.3% year over year. Reported earnings were $1.21 per share, modestly above the $1.18 consensus. Net income attributable to the company fell to $145 million from $284 million a year earlier, primarily reflecting a $150 million non-cash impairment charge related to pelacarsen.
Adjusted EBITDA was $840 million, up 8% from $779 million, while Portfolio Cash Flow rose 2% to $673 million. Net cash provided by operating activities slipped 2% to $686 million. Management raised its full-year 2026 Portfolio Receipts outlook to $3.50 billion–$3.55 billion, up from $3.40 billion–$3.50 billion, implying Royalty Receipts growth of 10%–11%.
Market Reaction and Investor Sentiment
Royalty Pharma shares edged lower following the report despite results that topped earnings-per-share expectations and a third consecutive guidance increase. The muted reaction reflected investor focus on several cross-currents. The GAAP revenue line of $690 million landed well below consensus estimates near $876 million, though analysts attributed much of that gap to a mismatch between the cash-based Portfolio Receipts metric and the accounting-based revenue figure. The $150 million pelacarsen impairment and the decline in GAAP net income also weighed on sentiment. Meanwhile, the slowdown in quarterly Royalty Receipts growth — from double-digit levels earlier in 2026 to 9% in Q3 — prompted some investors to weigh deceleration against the still-strong year-to-date performance.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will watch whether Royalty Pharma's newer royalty assets can continue offsetting erosion in legacy products. Growth drivers such as Tremfya, Voranigo, Evrysdi, and Imdelltra have carried the portfolio so far, but Promacta and Imbruvica declines remain a structural drag that management must absorb while sustaining double-digit Royalty Receipts growth.
Guidance will be a central focus. The raised full-year 2026 range of $3.50 billion–$3.55 billion implies Royalty Receipts growth of 10%–11%, and excludes any benefit from future acquisitions. Investors will also track capital deployment, with $1.9 billion in announced transactions this year, including royalties on Zoryve, Mimrylo, and cliramitug.
Beyond the numbers, several catalysts could shape sentiment in the months ahead. An upcoming FDA regulatory decision on GSK's neladalkib and Phase 3 results for Biogen's litifilimab in systemic lupus are among the near-term clinical events management highlighted. Margin trends and the timing of interest payments also bear watching, given that Portfolio Cash Flow margins dipped in the quarter largely due to the semi-annual debt-payment schedule. Return metrics remained stable, with return on invested capital at 14.3% and return on invested equity at 20.2% over the trailing twelve months. From what I see, the balance between new acquisitions and legacy offsets remains the key variable to track.
Using AI Tools in My Research
I often turn to Tickeron’s AI Screener when reviewing earnings like these. It helps me quickly filter healthcare royalty names and compare technical signals, fundamentals, and performance trends against peers. This approach gives me a clearer view of where Royalty Pharma stands relative to similar holdings without spending hours on manual screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RPRX in upward trend: price rose above 50-day moving average on October 15, 2026
RPRX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 48 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RPRX as a result. In 48 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for RPRX just turned positive on October 14, 2026. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in 28 of 50 cases over the following month. The odds of a continued upward trend are 56%.
The 10-day moving average for RPRX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 40%.
Following a +3.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in 174 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.
RPRX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RPRX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 17 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.403) is normal, around the industry mean (2.904). P/E Ratio (36.128) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (1.360) is also within normal values, averaging (9.059). Dividend Yield (0.014) settles around the average of (128.314) among similar stocks. P/S Ratio (12.870) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of drug development services
Industry Biotechnology
Advertisement